March Biosciences (March Bio) announced that the first patient has been dosed in its Phase II clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma. “This represents a significant milestone in advancing MB-105 as a potential treatment… Read More
DDW Editor Reece Armstrong speaks to Sarah Hein, CEO and Co-founder of March Biosciences, about the company’s recent fundraising efforts and its development of CAR-T therapies addressing challenging blood cancers. RA: What are the limitations of current standard-of-care therapies for blood cancers? SH: There are many treatment options for the… Read More
The US Food and Drug Administration (FDA) has granted orphan drug designation to MB-105, March Biosciences’ CD5-targeted CAR-T cell therapy for the treatment of relapsed/refractory CD5-positive T-cell lymphoma (TCL). MB-105 is in development as a treatment for TCL, T-cell acute lymphoblastic leukaemia (T-ALL), chronic lymphocytic leukaemia (CLL), and mantle cell… Read More
Biotechnology company March Biosciences (March Bio) has announced the close of a $28.4 million oversubscribed Series A financing, having raised over $51 million to date. Mission BioCapital and 4BIO Capital led the financing, with participation from KdT Ventures, Alexandria Venture Investments, Volnay Therapeutics, Modi Ventures, and Mansueto Investments. Existing investors… Read More
